Altimmune, Inc. (3G0.F)
Frankfurt · EUR · Healthcare · Biotechnology
€1.81 (+0.89%) as of
Key statistics
- Market cap
- 352.47M
- Forward P/E
- -1.01
- EPS (TTM)
- -0.6100
- Dividend yield
- 0.00%
- 52-week range
- 1.7940 – 5.3220
- Beta
- 0.06
- Revenue (TTM)
- 31k
- Profit margin
- 0.00%
- Volume
- 750.00
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Gaithersburg, MD, United States
- Employees
- 57
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.